- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular Lymphoma
Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.
Elizabeth Lihua Budde, MD, PhD, an assistant professor at City of Hope, discusses how a phase I/Ib clinical trial evaluating mosunetuzumab in patients with follicular lymphoma (FL) is different than other clinical trials.
Patients receive this novel treatment for a limited number of cycles, Budde says. Initial treatment is only 8 cycles, and the patient may remain in follow-up rather than being treated until progression or relapse.